{'fraction_non_alphanumeric': 0.025280898876404494, 'fraction_numerical': 0.0, 'mean_word_length': 5.723270440251572, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Metabolic syndrome during female midlife: what are the risks?

Abstract The metabolic syndrome (METS) is an entity diagnosed by three or more of the following factors: abdominal obesity, low high-density lipoprotein cholesterol, and high serum triglycerides, fasting glucose, and/or blood pressure levels. Abdominal obesity is the most prevalent component of the syndrome that favors insulin resistance and a proinflammatory and prothrombotic status, and the risk of developing diabetes, hypertension, and other chronic conditions. During the menopausal transition, women tend to gain weight and this has been related to an increase in the prevalence of the METS. Rates have also been linked to hormonal status (perimenopausal vs. postmenopausal), changes in lifestyle, and endocrine adjustments. Abnormal cytokine secretion subsequently produces endothelial dysfunction, which will consequently increase cardiovascular risk and related morbidity and mortality. This document will review the various risks that arise as a consequence of the METS during female midlife.